{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:02:09Z","timestamp":1769176929003,"version":"3.49.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.kint.2021.09.010","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T04:03:04Z","timestamp":1637208184000},"page":"1158-1160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase"],"prefix":"10.1016","volume":"100","author":[{"given":"Ryo","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-9008","authenticated-orcid":false,"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.09.010_bib1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.kint.2020.06.046","article-title":"KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer","volume":"98","author":"Porta","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.09.010_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.kint.2021.09.010_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2021.09.010_bib4","doi-asserted-by":"crossref","unstructured":"Bai Y, Kim JY, Bisunke B, et\u00a0al. Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney Int. 2021;100:1214\u20131226.","DOI":"10.1016\/j.kint.2021.08.022"},{"key":"10.1016\/j.kint.2021.09.010_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acschembio.5b01063","article-title":"Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors","volume":"11","author":"Klaeger","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.kint.2021.09.010_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI1347","article-title":"Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation","volume":"102","author":"Bloomer","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.09.010_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","article-title":"New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma","volume":"78","author":"Teuma","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.kint.2021.09.010_bib8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00280-017-3300-2","article-title":"Adjunction of a MEK inhibitor to vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury","volume":"79","author":"Teuma","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.kint.2021.09.010_bib9","doi-asserted-by":"crossref","first-page":"1255784","DOI":"10.1126\/science.1255784","article-title":"Tracking cancer drugs in living cells by thermal profiling of the proteome","volume":"346","author":"Savitski","year":"2014","journal-title":"Science"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821008711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821008711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:05:13Z","timestamp":1769173513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821008711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0085253821008711"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.09.010","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.06.046","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.08.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}